Novo Nordisk A/S
NVO · Healthcare
$45.12
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
2 Stocks Down 8% or More That Are Screaming Buys Right Now
The article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide is entering a competitive obesity market dominated by Novo Nordisk and Eli Lilly. The drug showed up to 20% average weight loss in phase II trials and offers a key advantage with once-monthly or less-frequent dosing compared to weekly injections from competitors. While MariTide trails competitors' efficacy and market presence, the massive obesity market projected to reach $114 billion by 2030 could support multiple players, allowing MariTide to carve out a meaningful position based on convenience and adherence.
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.
Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer
Resalis Therapeutics announced the appointment of Dr. Diana M. Røpcke as Chief Medical Officer to lead clinical strategy for RES-010, an antisense oligonucleotide in Phase 1b trials for obesity treatment. Dr. Røpcke brings extensive experience from Novo Nordisk in clinical drug development and cardiometabolic therapies.
NexLife Expands Flat-Rate Compounded GLP-1 Program With Microdose and Sublingual Protocols
NexLife, a physician-led telehealth platform, announced expanded compounded GLP-1 programs with flat-rate pricing that remains constant across all dose levels, ranging from $119-$169 monthly depending on medication and plan length. The service includes $377 in bundled nutrition, coaching, and provider support at no additional cost, independent batch testing, and expedited delivery.